NCT07244770

The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Beni-Suef University · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.

Detailed description

Older people suffering from Type 2 Diabetes Mellitus possess a major risk for age related cognitive dysfunction and dementia, mainly due to vascular complications. SGLT2 inhibitors and DPP4 inhibitors are antidiabetic medications, have shown promise not only in glycemic control but also in potentially mitigating cognitive decline and depressive symptoms.

Conditions

• MCI

Interventions

Type	Name	Description
DRUG	SGLT2 Is+METFORMIN	Patients administering SGLT2 Is+metformin added to their treatment for at least the past 12 months
DRUG	DPP4 Is+metformin	Patients administering DPP4 I+ metformin added to their treatment for at least the past 12 months
DRUG	Control group	patients administered their standard of care without any changes for the past 6 months

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-06-01
• Completion: 2026-12-30
• First posted: 2025-11-24
• Last updated: 2026-01-30

Locations

1 site across 1 country: Egypt